Eagle Asset Management Inc. bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,540,616 shares of the biopharmaceutical company’s stock, valued at approximately $23,894,000. Eagle Asset Management Inc. owned 1.05% of Halozyme Therapeutics at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in HALO. FMR LLC boosted its holdings in Halozyme Therapeutics by 5.0% in the first quarter. FMR LLC now owns 2,685,575 shares of the biopharmaceutical company’s stock valued at $43,238,000 after purchasing an additional 127,379 shares during the period. First Trust Advisors LP boosted its holdings in Halozyme Therapeutics by 18.6% in the first quarter. First Trust Advisors LP now owns 97,659 shares of the biopharmaceutical company’s stock valued at $1,572,000 after purchasing an additional 15,320 shares during the period. Arbor Investment Advisors LLC purchased a new position in Halozyme Therapeutics in the second quarter valued at $308,000. CWM Advisors LLC purchased a new position in Halozyme Therapeutics in the second quarter valued at $175,000. Finally, Taylor Wealth Management Partners boosted its holdings in Halozyme Therapeutics by 0.4% in the second quarter. Taylor Wealth Management Partners now owns 205,084 shares of the biopharmaceutical company’s stock valued at $3,523,000 after purchasing an additional 735 shares during the period. Hedge funds and other institutional investors own 82.50% of the company’s stock.
A number of research firms recently issued reports on HALO. BidaskClub lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 target price for the company in a report on Thursday. ValuEngine lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 21st. Finally, Barclays upgraded Halozyme Therapeutics from an “underweight” rating to an “equal weight” rating and decreased their target price for the company from $17.00 to $16.00 in a report on Tuesday, November 5th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $20.50.
Halozyme Therapeutics Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Recommended Story: Are analyst ratings accurate?
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.